Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku 18 lat lub starsze.
- •Pacjenci z potwierdzonym badaniem histologicznym rakiem pęcherza moczowego z przerzutami.
- •Pacjenci z potwierdzonym rakiem piersi, który ma określone cechy (HR+ i HER2-).
- •Pacjenci z rakiem piersi potrójnie ujemnym (TNBC).
- •Pacjenci z nieoperacyjnym lub przerzutowym niedrobnokomórkowym rakiem płuca (NSCLC).
✗ Disqualifies
- •Kobiety w ciąży lub karmiące piersią.
- •Kobiety w wieku rozrodczym, które są w ciąży lub karmią piersią.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
Research Facility
St Leonards, Australia
Research Facility
Nedlands, Australia
Research Facility
Perth, Australia
Research Facility
Christchurch, New Zealand
Trial contact
RayzeBio Clinical Trials
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/30/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.